

Luciana De Luca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3512068/publications.pdf>

Version: 2024-02-01

36
papers

1,684
citations

331670

21
h-index

330143

37
g-index

38
all docs

38
docs citations

38
times ranked

3115
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute Myeloid Leukemia Cells Functionally Compromise Hematopoietic Stem/Progenitor Cells Inhibiting Normal Hematopoiesis Through the Release of Extracellular Vesicles. <i>Frontiers in Oncology</i> , 2022, 12, 824562.	2.8	5
2	Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy. <i>Leukemia</i> , 2021, 35, 661-678.	7.2	40
3	Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 3141-3160.	6.7	14
4	Multiple Myeloma-Derived Extracellular Vesicles Impair Normal Hematopoiesis by Acting on Hematopoietic Stem and Progenitor Cells. <i>Frontiers in Medicine</i> , 2021, 8, 793040.	2.6	7
5	Advances in <i>Azorella glabra</i> Wedd. Extract Research: In Vitro Antioxidant Activity, Antiproliferative Effects on Acute Myeloid Leukemia Cells and Bioactive Compound Characterization. <i>Molecules</i> , 2020, 25, 4890.	3.8	4
6	A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain. <i>Molecular Cytogenetics</i> , 2019, 12, 32.	0.9	1
7	Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells. <i>Stem Cell Research and Therapy</i> , 2019, 10, 171.	5.5	5
8	DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation. <i>Stem Cell Research and Therapy</i> , 2019, 10, 138.	5.5	12
9	An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 249-258.	3.1	20
10	Future in the Past: <i>Azorella glabra</i> Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3348.	4.1	17
11	Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies. <i>Stem Cells International</i> , 2018, 2018, 1-11.	2.5	47
12	MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 460.	4.1	62
13	Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2017, 8, e2849-e2849.	6.3	32
14	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 483-496.	4.4	15
15	Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1424-1432.	1.3	43
16	MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 97-103.	4.4	65
17	Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1022.	4.1	36
18	Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1183.	4.1	31

#	ARTICLE	IF	CITATIONS
19	Epha3 acts as proangiogenic factor in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 34298-34309.	1.8	23
20	A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies. <i>Frontiers in Pharmacology</i> , 2016, 7, 416.	3.5	8
21	P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. <i>Frontiers in Pharmacology</i> , 2016, 7, 491.	3.5	27
22	MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. <i>Oncotarget</i> , 2016, 7, 6676-6692.	1.8	86
23	Dissecting chronic lymphocytic leukemia with 13q- using microRNA expression profile. <i>Leukemia Research</i> , 2016, 47, 114-115.	0.8	3
24	Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 217-225.	1.8	2
25	A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. <i>Oncotarget</i> , 2016, 7, 65171-65184.	1.8	18
26	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. <i>Oncotarget</i> , 2016, 7, 12951-12961.	1.8	28
27	Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2015, 16, 17514-17534.	4.1	23
28	High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. <i>Tumor Biology</i> , 2015, 36, 9739-9752.	1.8	159
29	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014, 28, 1922-1926.	7.2	55
30	Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. <i>American Journal of Hematology</i> , 2013, 88, 16-23.	4.1	60
31	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 520-530.	0.8	17
32	Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 3247-3258.	7.0	50
33	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. <i>Journal of Experimental Medicine</i> , 2013, 210, 951-968.	8.5	121
34	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 3130-3142.	7.0	86
35	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. <i>Journal of Cell Biology</i> , 2013, 201, i4-i4.	5.2	0
36	MicroRNAs: New Players in Multiple Myeloma. <i>Frontiers in Genetics</i> , 2011, 2, 22.	2.3	37